Natco Pharma receives EIR for its Vizag facility

Natco Pharma announced the successful closure and receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag), Andhra Pradesh, India, for an inspection conducted during the period from 24 March to 30 March, 2020.

Powered by Capital Market - Live News